Skip to content

Molecular and Clinical Profile of Von Willebrand Disease in Spain

Molecular and Clinical Profile of Von Willebrand Disease (VWD) in Spain (PCM-EVW-ES). Recruitment Extension, Further Data Analysis, Improvement of Registry Platform, Diagnosis and Management of VWD Application Development

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02869074
Acronym
PCM-EVW-ES
Enrollment
790
Registered
2016-08-16
Start date
2017-10-03
Completion date
2021-09-25
Last updated
2025-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von Willebrand Disease

Keywords

von Willebrand disease (VWD), von Willebrand factor (VWF), von Willebrand factor gene, next generation sequencing, diagnosis, VWD Spanish Cohort

Brief summary

The present Project is a third phase of the previous PCM-EVW-ES Project (Batlle et al. Thromb & Haemost 2015) with the aim of its extension, further analysis with an innovation development in the field of von Willebrand disease (VWD) based in the newer recently available methodologies. The aim of this project is to help the physician in a more uniform characterization and therapy of VWD in clinical practice, at an international level. A reduction of the expenses in the diagnosis process by using the new methodologies is pursued.

Detailed description

The present Project is a third phase of the previous PCM-EVW-ES Project (Batlle et al. Thromb & Haemost 2015) with the aim of its extension, further analysis with an innovation development in the field of von Willebrand disease (VWD) based in the newer recently available methodologies. The aim of this project is to help the physician in a more uniform characterization and therapy of VWD in clinical practice, at an international level. A reduction of the expenses in the diagnosis process by using the new methodologies is pursued. The specific objectives and corresponding tasks of the present project are as follows: 1\. Extension of the central phenotypic and next generation sequencing (NGS) genotypic characterization of the VWD in Spain, through the prospective recruitment in the Spanish VWD cohort of approximately 500 new patients with local historical VWD diagnosis (from approximately 38 centres). i. Improvement of the registry portal and database. ii. Recruitment criteria, phenotypic and genetic analysis of new recruited patients. In silico studies of novel von Willebrand factor gene (VWF) mutations iii. Analysis/investigation of the potential interrelationship between different clinical, phenotypic and genetic variations of the all recruited patients. iv. Validation/confirmation of the PCM-EVW-ES of the new initial diagnostic proposed algorithm including VWF NGS analysis. This project involves leading innovation and translational research with a direct impact on the quality of clinical care (applicability). To our knowledge there is no similar project in this field. Potential patents may derive from this project. It involves also development of e-learning and new information technologies (debates forum, ads, google search engine). This project may promote international collaboration. Development of an algorithmic platform that facilitates diagnosis and therapy orientation of VWD in clinical practice using the selected data from the overwhelming amount of information that new technologies, such as NGS, are producing.

Interventions

GENETICVWF gene analysis

52 exons adjacent intronic regions and promotor of VWF will be analyzed

Sponsors

Francisco Vidal Pérez
CollaboratorUNKNOWN
Maria Fernanda López Fernández
CollaboratorUNKNOWN
Almudena Pérez Rodríguez
CollaboratorUNKNOWN
Irene Corrales Insa
CollaboratorUNKNOWN
Ana Rosa Cid Haro
CollaboratorUNKNOWN
Spanish Society of Thrombosis and Haemostasis
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

One or more of the following: 1. VWF ≤ 30 IU/d, in 2 or more occasions. 2. Presence of multimeric abnormalities. 3. If isolated FVIII deficiency demonstration of decreased FVIII binding. 4. Presence of some VWF mutation. 5. ↑ RIPA at low concentrations of ristocetin.

Exclusion criteria

1. Presence of any data suggesting AVWS. 2. Absence of a signed patient informed consent

Design outcomes

Primary

MeasureTime frameDescription
Central diagnosis of 400 new VWD Spanish patientsJanuary 2019Phenotype and genetic central diagnosis of 400 new VWD Spanish patients. With determinations in samples obtained after patients recruitment, VWF NGS sequencing carried out in all patients, for exons 1 to 52, adjacent intronic regions and aproximately 1300 bp of promotor region. A pheno-genotype will be made With a final diagnosis assignment Evaluation of pheno/genotype congruence

Secondary

MeasureTime frameDescription
PCM-EVW-ES project algorithm validation/confirmationJanuary 2019Evaluation of the algorithm with data from the Spanish Registry patients. Mutation results will be used in the first line of VWD diagnosis Correlation between mutations and phenotype
Potential collaboration with the International Society on Thrombosis and HaemostasisJanuary 2019Proposal for evaluation of the PCM-EVW-ES algorithm with data from other international VWD patients cohorts

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026